These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 8883841

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.
    McCaleb ML, McKean ML, Hohman TC, Laver N, Robison WG.
    Diabetologia; 1991 Oct; 34(10):695-701. PubMed ID: 1959701
    [Abstract] [Full Text] [Related]

  • 3. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA, Cameron NE, Hohman TC.
    J Peripher Nerv Syst; 1998 Oct; 3(3):217-23. PubMed ID: 10959252
    [Abstract] [Full Text] [Related]

  • 4. Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat.
    McCaleb ML, Sredy J, Millen J, Ackerman DM, Dvornik D.
    J Diabet Complications; 1988 Oct; 2(1):16-8. PubMed ID: 2968349
    [Abstract] [Full Text] [Related]

  • 5. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy.
    Passariello N, Sepe J, Marrazzo G, De Cicco A, Peluso A, Pisano MC, Sgambato S, Tesauro P, D'Onofrio F.
    Diabetes Care; 1993 May; 16(5):789-95. PubMed ID: 8495620
    [Abstract] [Full Text] [Related]

  • 6. Effects of sulfonylureas, alpha-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes.
    Biederman JI, Vera E, Rankhaniya R, Hassett C, Giannico G, Yee J, Cortes P.
    Kidney Int; 2005 Feb; 67(2):554-65. PubMed ID: 15673303
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
    Gross ML, El-Shakmak A, Szábó A, Koch A, Kuhlmann A, Münter K, Ritz E, Amann K.
    Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Disparate effects of castration on renal structure and function in the streptozotocin diabetic rat.
    Bach LA, Cooper ME, Vranes D, Allen TJ, Rumble J, Jerums G.
    Diabetes Res; 1994 Jun; 27(1):27-38. PubMed ID: 7648794
    [Abstract] [Full Text] [Related]

  • 12. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats.
    Malatiali S, Francis I, Barac-Nieto M.
    Exp Diabetes Res; 2008 Jun; 2008():305403. PubMed ID: 18769499
    [Abstract] [Full Text] [Related]

  • 13. L-Citrulline, but not L-arginine, prevents diabetes mellitus-induced glomerular hyperfiltration and proteinuria in rat.
    Persson P, Fasching A, Teerlink T, Hansell P, Palm F.
    Hypertension; 2014 Aug; 64(2):323-9. PubMed ID: 24866144
    [Abstract] [Full Text] [Related]

  • 14. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
    Itagaki I, Shimizu K, Kamanaka Y, Ebata K, Kikkawa R, Haneda M, Shigeta Y.
    Diabetes Res Clin Pract; 1994 Oct; 25(3):147-54. PubMed ID: 7851268
    [Abstract] [Full Text] [Related]

  • 15. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
    Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R.
    FASEB J; 2000 Mar; 14(3):439-47. PubMed ID: 10698958
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus.
    Chang WP, Dimitriadis E, Allen T, Dunlop ME, Cooper M, Larkins RG.
    Diabetologia; 1991 Apr; 34(4):225-31. PubMed ID: 1906023
    [Abstract] [Full Text] [Related]

  • 18. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats.
    Sassy-Prigent C, Heudes D, Mandet C, Bélair MF, Michel O, Perdereau B, Bariéty J, Bruneval P.
    Diabetes; 2000 Mar; 49(3):466-75. PubMed ID: 10868970
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Glomerular basement membrane thickening in streptozotocin diabetic rats despite treatment with an aldose reductase inhibitor.
    Osterby R, Gundersen HJ.
    J Diabet Complications; 1989 Mar; 3(3):149-53. PubMed ID: 2528558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.